Literature DB >> 11257622

Prognostic significance of pulmonary lymphangioleiomyomatosis histologic score.

K Matsui1, M B Beasley, W K Nelson, P M Barnes, J Bechtle, R Falk, V J Ferrans, J Moss, W D Travis.   

Abstract

Correlations were made between clinical and follow-up data and histopathologic findings in 105 women (mean age +/- standard deviation, 38.3 +/- 9.0 years) with pulmonary lymphangioleiomyomatosis (LAM). The actuarial survival (to pulmonary transplantation or death) of the patients from the time of lung biopsy was 85.1% and 71.0% after 5 and 10 years respectively. The histologic severity of LAM, graded as a LAM histologic score (LHS), was determined on the basis of semiquantitative estimation of the percentage of tissue involvement by the two major features of LAM: the cystic lesions and the infiltration by abnormal smooth muscle cells (LAM cells) in each case: LHS-1, <25%; LHS-2, 25% to 50%; and LHS-3, >50%. Analysis using the Kaplan-Meier method revealed significant differences in survival for patients with LHS-1, -2, and -3 (p = 0.01). The 5-and 10-year survivals were 100% and 100% for LHS-1, 81.2% and 74.4% for LHS-2, and 62.8% and 52.4% for LHS-3. Increased degrees of accumulation of hemosiderin in macrophages also were associated with higher LHS scores (p = 0.029) and a worse prognosis (p = 0.0012). Thus, the current study suggests that the LHS may provide a basis for determining the prognosis of LAM.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11257622     DOI: 10.1097/00000478-200104000-00007

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  28 in total

1.  Erythropoietin-driven proliferation of cells with mutations in the tumor suppressor gene TSC2.

Authors:  Yoshihiko Ikeda; Angelo M Taveira-DaSilva; Gustavo Pacheco-Rodriguez; Wendy K Steagall; Souheil El-Chemaly; Bernadette R Gochuico; Rose M May; Olanda M Hathaway; Shaowei Li; Ji-an Wang; Thomas N Darling; Mario Stylianou; Joel Moss
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2010-10-29       Impact factor: 5.464

2.  Lymphangioleiomyomatosis--presence of receptor tyrosine kinases and the angiogenesis factor VEGF-A as potential therapeutic targets.

Authors:  Henrik Watz; Knut Engels; Siegfried Loeschke; Michael Amthor; Detlef Kirsten; Helgo Magnussen
Journal:  Thorax       Date:  2007-06       Impact factor: 9.139

3.  Effect of fasting on the size of lymphangioleiomyomas in patients with lymphangioleiomyomatosis.

Authors:  Angelo M Taveira-DaSilva; Amanda M Jones; Patricia Julien-Williams; Thomas Shawker; Connie G Glasgow; Mario Stylianou; Joel Moss
Journal:  Chest       Date:  2015-10       Impact factor: 9.410

Review 4.  Pulmonary Lymphangioleiomyomatosis: A Case Report and Literature Review.

Authors:  Sakda Sathirareuangchai; David Shimizu; Koah Robin Vierkoetter
Journal:  Hawaii J Health Soc Welf       Date:  2020-07-01

5.  Involvement of lymphatics in lymphangioleiomyomatosis.

Authors:  Connie G Glasgow; Angelo Taveira-DaSilva; Gustavo Pacheco-Rodriguez; Wendy K Steagall; Katsuya Tsukada; Xiong Cai; Souheil El-Chemaly; Joel Moss
Journal:  Lymphat Res Biol       Date:  2009-12       Impact factor: 2.589

6.  The natural history of lymphangioleiomyomatosis: markers of severity, rate of progression and prognosis.

Authors:  Angelo M Taveira-DaSilva; Gustavo Pacheco-Rodriguez; Joel Moss
Journal:  Lymphat Res Biol       Date:  2010-03       Impact factor: 2.589

7.  Predictors for clinical trial participation in the rare lung disease lymphangioleiomyomatosis.

Authors:  Brent W Kinder; A C Sherman; L R Young; J T Hagaman; N Oprescu; S Byrnes; Francis X McCormack
Journal:  Respir Med       Date:  2009-12-04       Impact factor: 3.415

8.  Pulmonary artery pressure in lymphangioleiomyomatosis: an echocardiographic study.

Authors:  Angelo M Taveira-DaSilva; Olanda M Hathaway; Vandana Sachdev; Yukitaka Shizukuda; Charles W Birdsall; Joel Moss
Journal:  Chest       Date:  2007-09-21       Impact factor: 9.410

9.  Clinical predictors of mortality and cause of death in lymphangioleiomyomatosis: a population-based registry.

Authors:  N Oprescu; F X McCormack; S Byrnes; B W Kinder
Journal:  Lung       Date:  2012-09-25       Impact factor: 2.584

Review 10.  Smooth muscle-like cells in pulmonary lymphangioleiomyomatosis.

Authors:  Vera P Krymskaya
Journal:  Proc Am Thorac Soc       Date:  2008-01-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.